Theravance (TBPH) Q1 Earnings Top, Revenues Match Estimates
Q1 2024 Theravance Biopharma Inc Earnings Call Transcript
Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates
Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
Theravance Biopharma to Participate in an Upcoming Investor Conference
Theravance Biopharma to Participate in an Upcoming Investor Conference
Catalent (CTLT) Reports Q3 Loss, Misses Revenue Estimates
Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024
Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024
Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024
BTIG Research Predicts Over 118% Rally for These 3 Stocks
BTIG Research Predicts Over 118% Rally for These 3 Stocks
Strength Seen in Theravance Bio (TBPH): Can Its 7.6% Jump Turn into More Strength?
Strength Seen in Theravance Bio (TBPH): Can Its 7.6% Jump Turn into More Strength?
Strength Seen in Theravance Bio (TBPH): Can Its 7.6% Jump Turn into More Strength?
Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024
Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024
Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue?
Why Is Theravance Bio (TBPH) Down 9% Since Last Earnings Report?
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.